Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Cash from Financing Activities (2016 - 2025)

Avanos Medical (AVNS) has disclosed Cash from Financing Activities for 13 consecutive years, with -$2.7 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 90.15% to -$2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$37.0 million through Dec 2025, up 24.64% year-over-year, with the annual reading at -$37.0 million for FY2025, 24.64% up from the prior year.
  • Cash from Financing Activities hit -$2.7 million in Q4 2025 for Avanos Medical, down from -$2.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $105.7 million in Q1 2022 to a low of -$114.7 million in Q4 2023.
  • Historically, Cash from Financing Activities has averaged -$8.9 million across 5 years, with a median of -$10.2 million in 2021.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 52950.0% in 2022 and later plummeted 4057.14% in 2025.
  • Year by year, Cash from Financing Activities stood at -$25.8 million in 2021, then increased by 15.12% to -$21.9 million in 2022, then crashed by 423.74% to -$114.7 million in 2023, then soared by 76.11% to -$27.4 million in 2024, then skyrocketed by 90.15% to -$2.7 million in 2025.
  • Business Quant data shows Cash from Financing Activities for AVNS at -$2.7 million in Q4 2025, -$2.0 million in Q3 2025, and -$3.2 million in Q2 2025.